JP Morgan Chase
KPRX icon

JP Morgan Chase’s Kiora Pharmaceuticals KPRX Stock Holding History

JP Morgan Chase’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$4 – 7558
2024
Q2 		$4 Buy
+1
New +$5 ﹤0.01% 7253
2024
Q1 		– Hold
0
– – – 7298

Other funds holding KPRX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's KPRX Position: Q3 2024 in Review

JP Morgan Chase sold out of Kiora Pharmaceuticals (KPRX) in Q3 2024, closing a stake of 1 share — an estimated $4 sold.

JP Morgan Chase first reported a position in KPRX in Q2 2024 and held it in 1 quarter. The position peaked at $4 in Q2 2024. 19 funds tracked by Wall St. Rank hold KPRX as of Q3 2024.

  • JP Morgan Chase reported no remaining Kiora Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • JP Morgan Chase sold 1 Kiora Pharmaceuticals share in Q3 2024, an estimated $4.
  • JP Morgan Chase first reported a position in Kiora Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • JP Morgan Chase's Kiora Pharmaceuticals position peaked at $4 in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.